“With every therapy added for repurposing, we are one step closer to finding treatments and hopefully cures for diseases.”

– Pharmaceutical Executive and Cures Within Reach Partner

“Repurposing is quicker, it’s cheaper and patients are better off for it, and that’s why I donate to Cures Within Reach.”

– Cures Within Reach Supporter

“With repurposing of already approved drugs or nutraceuticals, treatments can be obtained for patients much more quickly. Repurposing can literally save lives that would otherwise be lost.”

– Cures Within Reach Funded Researcher
Dear Stakeholders, Partners and Friends:

First, a sincere Thank You! to the many individuals and organizations that provided support to Cures Within Reach this fiscal year. We had a spectacular year, engaging in research with a number of new institutions, diseases and countries, adding academic and industry partners, funding new clinical repurposing research projects and spreading the “Repurposing Revolution” around the globe through writing and presenting about the importance of repurposing research.

Last September, our Executive Board formed a Strategic Planning Committee, which was volunteer-chaired by Barbara Goodman, iBIO Institute Senior VP, and included Executive and Business Advisory Board members and a number of independent experts in academia, industry, tech transfer, philanthropy and finance. Over the following six months, the Committee worked with Cures Within Reach staff to evaluate and strategize on how best to expand our mission to drive more treatments to more patients more quickly through repurposing. Now approved by the Cures Within Reach Executive Board, implementation began in FY2018.

At our June Global Health Repurposing Awards dinner, we honored researchers, clinicians, philanthropists, industry professionals, organizations and companies, for their pioneering repurposing work and positive patient impact. Our two-year-old CureAccelerator™ online platform eclipsed the 1,400-user mark and launched global Requests for Proposals. This repurposing research engine continues to be developed as the global hub of repurposing.

With your leadership and financial support, Cures Within Reach continues to develop collaborations that lead to high-impact repurposing projects, connecting researchers with funding sources, facilitating crowd sourcing and identifying alternative financing models and incentives for repurposing.

We have a lot more work to do to bring repurposed treatments and cures to the 7,000+ unsolved diseases that affect more than 500 million people across the globe. As the only disease-agnostic non-profit organization exclusively dedicated to repurposing research as a fast track to patient impact, we are growing our programs to scale outcomes while building new forms of organization sustainability.

Over the next several years, we will be dedicated to exploring generic drugs as a resource for unsolved diseases, harnessing emerging social finance mechanisms to create new financial incentives and strengthening our relationships with pharmaceutical, government and philanthropic partners.

We are excited about the year to come and the impact we can make together. We are grateful for your support.

Best,

Dr. Bruce Bloom, Chief Executive Officer       Margaret Christie, Executive Board Chair
Cures Within Reach is proud of the progress we’ve made in fiscal year 2017, ending July 31. Thank you to all of you who have played a role in our success. Below are some the highlights from FY2017.

Cures Within Reach Research Highlights

- CWR-funded research has resulted in **repurposed treatments for 13 indications**
- Since 2009, CWR has funded **62 completed repurposing research projects** valued at nearly **$6.3 million**, resulting in **over 50 published papers** with more in process
- Completed projects represent partnerships with **40 institutions in 6 countries**

Research Projects: FY2017

- **21 ongoing**, almost **$2.2 million** in funding
- Of those projects, **8 began in FY2017**
- **3 projects completed** in FY2017, 2 of which have already **published results** in peer-reviewed scientific journals

*Cures Within Reach creates patient impact by funding new and innovative repurposing research, adding to medical knowledge and patient care.*

Current CureAccelerator™ Stats

- **1,432** Active Users
- **187** Posted Projects
- **18** Published RFPs

*The CureAccelerator Community continues to grow, with more people and ideas coming together from all over the world at our central repurposing hub.*
CURES WITHIN REACH MISSION

Cures Within Reach improves patient quality and length of life by leveraging the unrealized clinical potential and missed therapeutic opportunities in existing medicine and science. We leverage the speed, safety and cost-effectiveness of medical repurposing research, driving more treatments to more patients more quickly, by clinically testing approved drugs, devices and nutraceuticals for unsolved disease indications that can serve both commercial and philanthropic needs.

CURES WITHIN REACH AS A VALUE-DRIVING CATALYST

Creating Patient Impact – Remembering Our “Why”

Cures Within Reach and our stakeholder partners are passionate about creating positive patient impact by developing “new” treatments through repurposing. Repurposing is particularly important in diseases where industry has a cost-benefit challenge, which include rare diseases, acute diseases and infectious diseases.

In FY2017, Cures Within Reach focused on repurposing in rare diseases as our theme for the year. We celebrated the 10th anniversary of funding one of our early success stories in rare diseases: repurposing sirolimus to treat autoimmune lymphoproliferative syndrome (ALPS). Diagnosed with ALPS at age two, Nicole was 13 years old and very sick when she was treated by Dr. David Teachey at the Children’s Hospital of Philadelphia as part of a Cures Within Reach funded clinical trial. Since that time, she has grown into a happy, thriving young adult. To all those that helped make her repurposed treatment a reality, Nicole says “You saved my life.” Cures Within Reach is proud to be a part of Nicole’s journey, and we’re looking forward to seeing what she does next.

“If you would have told me that these two little pills could save my daughter’s life, I never would have believed it. And yet, here we are many years later and she’s living an almost normal life. We’re so thankful for the researchers and funders that made this happen.” - Laura, Nicole’s Mom.
Catalyzing Repurposing Research in FY2017

Research Fast Facts:

- **21 total ongoing projects** in 17 different institutions, representing over $2 million in Cures Within Reach funding
- **8 new projects** approved in FY2017, valued at nearly $350,000
- **3 projects were completed**, all with data either published in peer-reviewed academic journals or being prepared for publication
- **4 projects already selected** for funding in FY2018, with more to come!

The Cures Within Reach repurposing research portfolio grew with eight new projects started in FY2017. Our ongoing repurposing projects now total 21. These projects cover a range of disease areas, including cancer, rare diseases, pediatric conditions, diabetes, Alzheimer’s disease, central nervous system disorders, heart failure, macular degeneration, depression and post-traumatic stress disorder. We are grateful for the support of our sponsors, donors and partners in making these exciting research studies a possibility.

<table>
<thead>
<tr>
<th>CURES WITHIN REACH OPEN PROJECTS – FY2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dr. Jeff Borgia</strong></td>
</tr>
<tr>
<td><strong>Dr. Zachary Cox</strong></td>
</tr>
<tr>
<td><strong>Dr. Ron Crystal</strong></td>
</tr>
<tr>
<td><strong>Dr. Rafael Davalos</strong></td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>-----------------------------</td>
</tr>
<tr>
<td>Dr. James Dowling, Dr. Carsten Bönnemann</td>
</tr>
<tr>
<td>Dr. Denise Faustman</td>
</tr>
<tr>
<td>Dr. Marc-Eric Halatsch</td>
</tr>
<tr>
<td>Dr. George Havelka, Dr. Darwin Eton</td>
</tr>
<tr>
<td>Dr. Kristen Hollinger</td>
</tr>
<tr>
<td>Dr. Stacy Kahn</td>
</tr>
<tr>
<td>Dr. Benjamin Kim</td>
</tr>
<tr>
<td>Dr. Krista Lanctôt</td>
</tr>
<tr>
<td>Dr. Sarah Leary</td>
</tr>
<tr>
<td>Dr. Michael Levine, Dr. Étienne Sochett</td>
</tr>
<tr>
<td>Dr. Desmond Oathes</td>
</tr>
<tr>
<td>Dr. Jyoti Patel</td>
</tr>
<tr>
<td>Dr. Azra Raza, Dr. Naomi Galili</td>
</tr>
<tr>
<td>Dr. Gregory Riggins</td>
</tr>
<tr>
<td>Dr. Chani Traube, Dr. Rita Alvarez</td>
</tr>
<tr>
<td>Dr. Logan Wink</td>
</tr>
<tr>
<td>Dr. James Young, Dr. Max Fitzgerald</td>
</tr>
</tbody>
</table>
International Partnership to Fund Rare Disease Research

In FY2017, Cures Within Reach and the Canadian Institutes of Health Research (CIHR) continued our partnership to spread the global reach of repurposing by co-funding repurposing research projects in rare diseases. The goals of this innovative program were to create treatments with positive patient impact and to increase cross-country collaboration. Operational support for the program was generously provided by the Mindset Foundation.

Of the eight projects started in FY2017, two were awarded joint funding through this partnership, and a third project was selected for funding through CIHR, with administrative support provided by Cures Within Reach:

- Dr. James Dowling and Dr. Carsten Bönnemann, The Hospital for Sick Children (Toronto, Canada) and the National Institutes of Health: *Tamoxifen Therapy for Myotubular Myopathy*

- Dr. Michael Levine and Dr. Étienne Sochett, Children’s Hospital of Philadelphia and the Hospital for Sick Children (Toronto, Canada): *Repurposing an Antibiotic to Treat a Defect in Vitamin D Metabolism*

- Dr. Murray Baron and Dr. Tracy Frech, Sir Mortimer B Davis Jewish General Hospital (Montreal, Canada) and the University of Utah: *Creating a Standardized Treatment Protocol for a Rare, Multi-System Disorder* (administrative support only)

Finding Treatments in a New Disease Area

Huntington’s disease is a rare, genetic neurological condition, where brain cells break down over time. There is currently no cure for Huntington’s disease, and only a few disease-modifying therapies exist. This year, Cures Within Reach issued its first Request for Proposals for Huntington’s disease, with up to $100,000 in funding available per project, and we received a number of solid repurposing clinical trial proposals. We will be funding at least one project in Huntington’s disease in FY2018 to help deliver treatments to reduce the symptoms or stop the progression of this debilitating and deadly disease.
Honoring Leaders at the Global Health Repurposing Awards

On June 27, 2017, Cures Within Reach hosted our 5th Annual Global Health Repurposing Awards (GHRA), with Judy Hsu from Chicago’s ABC 7 Eyewitness News as guest emcee. The 2017 GHRA brought together almost 300 supporters, stakeholders, friends and guests to honor leaders in industry, academia, medicine and philanthropy who are improving the lives of rare disease patients through repurposing. With one in ten Americans suffering from a rare disease, and many more suffering around the world, we were proud to help tell their stories. Cures Within Reach is grateful for critical funding raised to support our mission and create positive patient impact, which increased by 20% over our 2016 event. It was truly a wonderful and inspiring evening.

Cures Within Reach
Patient Impact Legacy Award

Timothy P. Walbert
Horizon Pharma plc

For his commitment to both repurposing research and to rare diseases, believing that the needs and concerns of patients must be central to any therapy development program

Janet Davidson Rowley
Patient Impact Research Award

Berish Rubin, PhD; Sylvia Anderson, PhD
Fordham University

For the creation of a multiple nutraceutical repurposing treatment regimen that has saved the lives of children with Familial Dysautonomia, a rare genetic nervous system disorder
**Golfing for Patient Impact**

Funding for our repurposing research portfolio comes in part from the Cures Within Reach Longest Day of Golf (LDOG) event. Our LDOG players raise money in the months leading up to the event, and then play as many holes as possible from dawn until dusk on the day of the event. For over a decade the LDOG has raised funding to support one or more repurposing clinical trials with the potential to change clinical care, and this year the golfers brought their “A” game.

“"The LDOG is a great opportunity to help patients while spending time with others who want to make a difference.”

— Steve Goodfriend, Longest Day of Golf Chair (far right)
In 2017, the golfers were able to **double their patient impact**, thanks to a generous supplemental donation from Goldman Philanthropic Partnerships. Two pediatric repurposing research clinical trials will be funded in FY2018:

- Dr. Evan Nadler, Children’s National Health System: *Using a Cancer Drug to Treat a Rare Pediatric Liver Disease*

- Dr. Ihab Suwwan, The Hospital for Sick Children (Toronto, Canada): *Low Level Laser Therapy for Prevention of Oral Mucositis in Pediatric Cancer Patients*

**Expanding Our Reach**

During FY2017, Cures Within Reach initiated two new repurposing collaborations to expand the reach and impact of our mission, by serving as the fiscal sponsor for these collaborations. **Cures Within Reach for Cancer**, a Boston-based initiative led by Laura Kleiman, PhD, focuses on funding and facilitating the development of repurposed drugs for cancer.

The three main goals of Cures Within Reach for Cancer are:

- Develop a sustainable model to fund Phase II/III clinical trial repurposing generic drugs to treat unsolved cancers or unmet cancer needs

- Advocate for scientifically validated repurposed treatments to be incorporated into the standard of care for cancer patients

- Create a publically available online “KnowledgeBase” containing curated information on all repurposed drugs and other therapies already proven effective in cancer

The second initiative, **Mission: Cure**, is using outcome-based financing and impact investing to demonstrate a new model for curing disease. Co-founded and led by Megan Golden, JD, Mission: Cure will pilot its mission in chronic pancreatitis, developing a playbook for building collaborations among key stakeholders to problem-solve the most promising ways to find a cure as quickly as possible. This approach, with repurposing research as a central strategy, can then be applied in other disease areas.
Building a Global Community on CureAccelerator™

CureAccelerator continues to be the premier online hub for repurposing research, where funders, researchers, clinicians, industry representatives, patient groups and government can come together to collaborate and drive repurposing forward.

In February, Cures Within Reach, along with our UK-based partners Findacure and Healx, launched our first global Rare Repurposing Open Call on CureAccelerator. The main goal of the Open Call was to demonstrate the huge potential of clinically ready, patient group-led and researcher-driven innovation in rare disease generic drug repurposing. We structured this Request for Proposals to identify a potential portfolio of suitable generic drug repurposing research clinical trials that would have the potential to improve patient outcomes and reduce healthcare costs for the Social Impact Bond investment structure we are working on with the English government.

As part of the Open Call, we added several new research project criteria on CureAccelerator, focusing on patient impact, collaboration and potential healthcare savings. This information will help us gather data to strengthen the case for repurposing, in an effort to encourage more funding partners to participate.

Researchers from around the globe posted their repurposing ideas on CureAccelerator, and we will reference these projects as we continue our conversations with National Health Service in England and Scotland, as well as other potential academic, government and industry partners.

The incredible response to the Rare Repurposing Open Call demonstrates the power of repurposing and CureAccelerator to build collaborations that can create patient impact.
**Cures Within Reach on the Global Stage**

Cures Within Reach continues to expand its global position as a thought-leader in the repurposing community through chairing, presenting at and participating in many conferences and meetings around the world.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>August</td>
<td>iBIO Institute’s Patient Advocacy Collaboration Translation, Chicago, IL University Partnerships in Repurposing Research Site Visit, Vanderbilt University</td>
</tr>
<tr>
<td>September</td>
<td>Discovery On Target Conference, Boston, MA “Drug Repurposing as a Strategy to Improve Patient Outcomes” Exponent Philanthropy National Conference, Chicago, IL “Repurposing Research for Prostate Cancer” poster presentation Guest blog: One Health of a Life “A Place to Teach Old Drugs New Tricks”</td>
</tr>
<tr>
<td>November</td>
<td>University Partnerships in Repurposing Research Site Visit, University of Michigan B-Debate: Drug Repurposing For Rare Diseases, Barcelona, Spain &quot;Social Finance: A New Economic Engine for Generic Drug Repurposing”</td>
</tr>
<tr>
<td>February</td>
<td>CureSearch Catapult Summit, Menlo Park, CA Podcast: Cures Within Reach at DIA 2017, “Good Therapies at Reasonable Cost Driving Insights to Action”</td>
</tr>
<tr>
<td>March</td>
<td>Rare Disease Legislative Advocates Rare Disease Congressional Caucus Briefing: Advancing Rare Disease Treatments in the Era of Cures and Health Care Reform, Washington, DC &quot;New Models for Rare Disease Drug Development” Publication: Pharmaceutical Patent Analyst, “The trials and tribulations of repurposing metformin and other generic drugs for tuberculosis”</td>
</tr>
<tr>
<td>June</td>
<td>Moderated panel at Drug Information Association Annual Meeting, Chicago, IL “Drug Repurposing: Where Will it Take Us?” 6th Annual Drug Repositioning, Repurposing and Rescue Conference Co-Chair, Chicago, IL “How to Build and Nurture Collaborations in Repurposing Research” Featured on Chicago’s ABC 7 Eyewitenss News “Medical Treatment Repurposes Drug, Could Potentially Save Limbs”</td>
</tr>
</tbody>
</table>
Looking forward to FY2018 and beyond

During FY2017, a group of eight Cures Within Reach volunteers, representing a wide variety of stakeholder groups, served for six months on our Strategic Planning Committee. The result was the development of a three-year Strategic Plan, to support our vision of catalyzing repurposing research and enabling and facilitating conversation and action among stakeholders that help transform healthcare through repurposing opportunities.

Now approved by the Executive Board, the implementation of this three-year plan has begun to take Cures Within Reach into our next stage of growth, both in terms of scale and long-term funding sources. We are pleased to share highlights of the strategic plan with our partners, supporters and friends.

Our New Value Proposition

1. Cures Within Reach serves as a Value-Driving Catalyst of repurposing opportunities and Value-Creating Facilitator funding research between the many stakeholders, with CureAccelerator as the Hub/Platform.

2. Cures Within Reach operates as a thought-leading, Value-Creating Facilitator of conversation and action in repurposing’s value to drive both market impact and health savings.

We will drive market impact and health savings:

To patients and patient groups  
With payers and the healthcare industry

From academia/researchers  
With support from the government, philanthropy and others
Implementing the Plan

In order to make progress on our goals described above, early in FY2018 Cures Within Reach promoted Bruce Bloom to CEO to increase his work in creating global partnerships, and hired Barbara Goodman as President & COO to help expand the reach and influence of Cures Within Reach in both the philanthropic and commercial spaces, as well as to foster organizational growth and financial sustainability.

We are excited about the new opportunities ahead of us, and we look forward to sharing our future success with you.

Our Goals

1. Solidify Cures Within Reach’s leadership role as Value-Creating Catalyst and Facilitator in repurposing
2. Expand Cures Within Reach’s self-sustaining funding sources to support future repurposing opportunities
3. Strengthen Cures Within Reach’s role as value-creating conversation and action among stakeholders interested in repurposing to address unrealized clinical potential
## CURRENT CURES WITHIN REACH STAFF

<table>
<thead>
<tr>
<th>Image</th>
<th>Name</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1.jpg" alt="Dr. Bruce Bloom" /></td>
<td>Dr. Bruce Bloom</td>
<td>Chief Executive Officer</td>
</tr>
<tr>
<td><img src="image2.jpg" alt="Barbara Goodman" /></td>
<td>Barbara Goodman</td>
<td>President &amp; Chief Operations Officer</td>
</tr>
<tr>
<td><img src="image3.jpg" alt="Clare Thibodeaux, PhD" /></td>
<td>Clare Thibodeaux, PhD</td>
<td>Director of Scientific Affairs</td>
</tr>
<tr>
<td><img src="image4.jpg" alt="Jessica Wayne" /></td>
<td>Jessica Wayne</td>
<td>Director of Sponsorships</td>
</tr>
<tr>
<td><img src="image5.jpg" alt="Susan Braze" /></td>
<td>Susan Braze</td>
<td>Administrative Manager</td>
</tr>
</tbody>
</table>

## FY2017 VOLUNTEER LEADERSHIP

### EXECUTIVE BOARD

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Margaret Christie, Chair</td>
<td>Chair</td>
</tr>
<tr>
<td>Golan Christie Taglia LLP</td>
<td></td>
</tr>
<tr>
<td>Steve Braun, Treasurer</td>
<td>Treasurer of Northwestern Mutual</td>
</tr>
<tr>
<td>Lucy Mancini-Newell, Secretary</td>
<td>Secretary of The Kiran Consortium Group LLC</td>
</tr>
<tr>
<td>Solveig Direnzo</td>
<td>President of Fresenius Kabi</td>
</tr>
<tr>
<td>Liz Downey</td>
<td>Treasurer of PwC</td>
</tr>
<tr>
<td>Richard Pless</td>
<td>Treasurer of Takeda</td>
</tr>
</tbody>
</table>

### BUSINESS ADVISORY BOARD

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donald Frail</td>
<td>Treasurer of Allergan</td>
</tr>
<tr>
<td>Ben Katz</td>
<td>Treasurer of HSBC</td>
</tr>
<tr>
<td>Stephen Naylor</td>
<td>Treasurer of MaiHealth Inc</td>
</tr>
<tr>
<td>Alan Goldberg</td>
<td>Treasurer of Conceptual Mindworks</td>
</tr>
<tr>
<td>Robert Metz</td>
<td>Treasurer of Horizon Pharma plc</td>
</tr>
<tr>
<td>Norbert Riedel</td>
<td>Treasurer of Aptinyx</td>
</tr>
</tbody>
</table>
Brian Roden  
Greenfield Chemical, Inc.  
Adriann Sax  
Fortress Biotech  
James Tyree  
Retired, Abbott

Michael Rosen  
Rosen BioScience Strategies  
Nancy Sullivan  
IllinoisVENTURES LLC

**SCIENCE ADVISORY BOARD**

Steve Kron, Chair  
University of Chicago  
Tim Cunniff  
Paragon Pharmaceuticals  
Shuli Kulak  
Fortress Biotech

Mitchell Seymour, Co-Chair  
University of Michigan  
Luis Caveda  
Pharma-Bio Serv  
Jeff Sherman  
Horizon Pharma plc

Russ B. Altman  
Stanford University  
Doug Feinstein  
University of Illinois at Chicago  
Larry Sklar  
University of New Mexico

Kevin Clark  
California NanoSystems Institute  
Andres Klein  
Universidad del Desarrollo

**YOUNG PROFESSIONALS BOARD**

Helen Ji, Executive Chair  
Schiff Hardin  
Tyler Bloom  
Kaitlin Lavery  
Rovio

Melvin McElrath, Vice-Chair  
Pfizer  
Alex Bobe  
University of Chicago  
Marine Lebrun  
Northwestern University

Yanran He, Media/Communications  
University of Chicago  
Mike Burrows  
University of Chicago  
Tom Rammer  
Schiff Hardin

Kim Woods, Membership  
University of Chicago  
Sona Dave  
IBM Watson  
Victor Simoes  
Innoblative Designs

Tyler Wanke, Fundraising  
Innoblative Designs  
Julia Egofske  
Horizon Pharma plc  
Jose-Marc Techner  
Feinberg School of Medicine

Maggie Arko  
Intouch Solutions  
Jonathan Gunn  
Briteseed  
Jessica Traver  
IntuiTap Medical

Jennifer Ball  
American Academy of Orthopaedic  
Surgeons  
Lisa Hamer  
Marsh  
Vysak Venkateswaran  
Deloitte Digital

Matthew Barnes  
West Monroe Partners  
Amanda Hirsch  
Diagnostic Photonics  
Mike Zhang  
University of Chicago  
Andre Iovane  
Northwestern University
STRATEGIC PLANNING COMMITTEE

Barbara Goodman, Chair
Gayle Kirkpatrick
 Consultant
Steve Kuemmerle
 University of Chicago

Robert Metz
Horizon Pharma plc

Renee Michaels
The Kinship Foundation

Matthew Rich
PwC

Michael Rosen
Rosen BioScience Strategies

Adriann Sax
Fortress Biotech

Nicole Walker
Baird Capital
FY2017 DONORS

$50,000+
- American Landmark Properties
- Anonymous
- Golan Christie Taglia
- Goldman Philanthropic Partnerships
- Jewish Federation of Metropolitan Chicago
- The Kahlert Foundation
- Pincus Family Fund

$10,000-49,999
- Joel & Mari Dysart
- HEALX
- Horizon Pharma
- The Lockwood Group
- Robert & Lori Miller
- The Patient Experience Project
- PricewaterhouseCoopers LLC
- Tonic Blue Communications
- Vision for Tomorrow Foundation
- Tim Walbert

$5,000-9,999
- CBRE
- Margaret Christie
- Cyclica
- Rachel & David Grund
- IBM Research
- Jazz Pharmaceuticals
- Susie Karkomi
- M&M Bank
- Wilson Dow Group

$1,000-4,999
- Anonymous
- Aptinyx
- Baxter Credit Union
- Brian & Laurel Bear
- Barbara Bloom
- Dan Bobear
- BriovaRx
- Cambridge BioMarketing
- Charity Services Centers
- Michael Desjardin
- Diabetes Charity of America
- Liz Downey
- Stephen and Lois Eisen
- Darvin Eton
- First Bank of Highland Park Foundation
- Scott Greenberg
- Tim Guiliams
- Scott & Carol Hennessy
- Judy Hsu
- Nancy Joseph-Ridge
- Steve Kron
- Carla Kupe-Arion
- Marcello’s
- Mark LaVarre
- Mark Meier
- Hope & Brad Mueller
- Pat Nichols
- Peter Panagiotaros
- PhRMA
- Matthew Rich
- Matthew Schecter
- Gurpreet Singh
- Regis Technologies
- TerSera Therapeutics
- Dennis Zymboly

$500-999
- Kristina Allikmets
- Duane Barone

- Steve Berkowitz
- Melissa Blunck
- Stephen and Nancy Bloom
- Al Capitanini
- Randy Carl
- Barbara Carley
- Matthew Cooney
- Trucia Drummond
- Lawrence M. Elman
- Steve Goldsher
- Healthcare Businesswomen's Association
- John Hirsch
- Inperity
- Kat Fish Realty
- Amy Klein
- Sherry Koppel
- Maria Mangler
- Kevin Manning
- Maryann Marsh
- Charles Maylee
- George Metzger
- Bob Muzikowski
- S. James Perlow & Sandra Jo Allen
- Dorothy J. Podl
- Michael Polsinelli
- Marc Pozan
- Desiree Quizon-Colquitt
- Alan Radcliffe
- Peter Regis
- Brian Roden
- Michael Rosenbaum
- Iven Rosheim
- David "Buzz" W. Ruttenberg
- Shogun Dojo
- William Singer
- Snackittome
- Mark Tatroe
- Michael Tepper
- Erica Vasquez
- James White
$250-499
-Thomas Arenberg
-Nathaniel Bailey
-Mark Behlke
-Eileen Bell
-Jeremy Bloom
-Bloomenkranz, Inc.
-Christine Boge-Hubbard
-Michael Brainin
-Mark Campbell
-James Cardelli
-Charlie Denison
-Meghanne Downes
-Rick Dusel
-Robert Dysart
-Laura Ferring
-Leland and Idia Fisher
-Foundation For Advancing Technology
-Marci Friedman
-Thomas C. & Darlene J. Furst
-Siobhan Gibney Gomis
-Barbara Goodman
-Gore Animal Foundation
-Martin Gradman
-Laurence Hayward
-Meg & John Hesselmann
-Zoe Hoeppner
-Thomas V. Hogan
-Cynthia Izzo
-Anup Khatta
-Binita Kwankin
-Kaitlin Lavery
-Karen Lewis
-Ward Lewis
-Frank and Janis Ling
-Chris Lovorn
-Dan Lyne
-Lucy Mancini-Newell
-Patrick Marschall
-Matthew Miller
-John Mueller
-Patricia Mueller
-Tom O’Connell
-Michael Onak
-Sacha Patera
-Rhonda Rickey

<$250
We appreciate every single donation, great or small. Thank you to every single member of our incredible family of supporters.
cureswithinreach.org

CureAccelerator.org

Twitter: CuresWReach

Facebook: CuresWithinReach

LinkedIn: Cures Within Reach

Cures Within Reach
Illinois Science + Technology Park
8025 Lamon Ave., Suite 440
Skokie, IL 60077
(847) 745-1245
info@cureswithinreach.org